Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | OCT measures association with serum/CSF biomarkers in CIS patients

Jaume Sastre-Garriga, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses a study that analyzed the association between optical coherence tomography (OCT) measures and serum/cerebrospinal fluid (CSF) biomarkers in patients diagnosed with clinically isolated syndrome (CIS). OCT measures and other biological determinations, such as neurofilament light chain (NfL) and glial fibrillar acidic protein (GFAP), have been associated with markers of disease severity. However, the study results didn’t show any correlation between OCT measures and serum/CSF biomarkers, suggesting that, at the earliest stages, retinal and biological biomarkers are probably measuring different aspects of the disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J Sastre-Garriga has received grants and personal fees from Genzyme, personal fees from Almirall, Biogen, Celgene, Merck, Bayer, Biopass, Bial, Novartis, Roche and Teva, and he is European co-Editor of Multiple Sclerosis Journal and Scientific Director of Revista de Neurologia.